Kaleido Biosciences Revenue and Competitors

License our Company Data API

$230.9M

Total Funding

Estimated Revenue & Valuation

Kaleido Biosciences's estimated annual revenue is currently $855k per year.(i)
Kaleido Biosciences received $101.0M in venture funding in June 2018.
Kaleido Biosciences's estimated revenue per employee is $53,438
Kaleido Biosciences's total funding is $230.9M.
Kaleido Biosciences's current valuation is $94.1M. (January 2022)

Employee Data

Kaleido Biosciences has 16 Employees.(i)
Kaleido Biosciences grew their employee count by -6% last year.

Kaleido Biosciences's People

Name	Title	Email/Phone
1 Susan Stewart	Chief Regulatory Affairs – Advisor	Reveal Email/Phone
2 Ulrich Binne	Head Intellectual Property, VP	Reveal Email/Phone
3 Mark Wingertzah...	SVP R&D and Head Development	Reveal Email/Phone
4 Heather Vaz	VP Quality Assurance & Quality Control	Reveal Email/Phone
5 Jonathan Lawren...	Executive Director and Head Chemistry	Reveal Email/Phone
6 Zhengzheng Pan	Senior Director Analytical Development	Reveal Email/Phone
7 James Brown	Senior Director, Computational Biology and Integrated Data Science	Reveal Email/Phone
8 William Duke	Chief Financial Officer	Reveal Email/Phone
9 Steven Fukuda	Sr. Clinical Project Manager	Reveal Email/Phone
10 Hoa Luong	Sr. Manager, Pilot Plant	Reveal Email/Phone

Kaleido Biosciences Competitors & AlternativesAdd Company

Competitor Name	Revenue	Number of Employees	Employee Growth	Total Funding	Valuation
#1 InCrowd	$5.3M	68	11%	$3M	N/A
#2 DrugPatentWatch...	$1.4M	7	N/A	N/A	N/A
#3 Atomwise	$15.7M	78	-26%	$176.6M	N/A
#4 Thermo Fisher S...	$39060M	98035	0%	$30 b	$234.4B
#5 DrugDev	$130.9M	651	N/A	N/A	N/A
#6 Document Soluti...	$25.7M	161	N/A	N/A	N/A
#7 Schrödinger	$124.8M	910	1%	$567.2M	$2.2B
#8 Advera Health A...	$1.2M	14	N/A	N/A	N/A
#9 Naked Biome	$0.9M	6	N/A	N/A	N/A
#10 Bruker Corporat...	$2360M	4804	7%	$22.5M	$10.7B
#11 Chemical Comput...	$12.2M	79	N/A	N/A	N/A
#12 Certara	$275.4M	1554	7%	N/A	$4.4B
#13 Optibrium	$11.2M	72	3%	N/A	N/A
#14 Olympus Life Sc...	$12.6M	57	-15%	N/A	N/A
#15 Adjility Inform...	$0.1M	4	N/A	N/A	N/A
#16 De Novo Softwar...	$2.7M	27	N/A	N/A	N/A
#17 Genedata	$87.4M	564	N/A	N/A	N/A
#18 Gritstone Oncol...	$46.5M	233	2%	$396M	$424.9M
#19 American Gene T...	$8.4M	54	N/A	N/A	N/A
#20 Eidogen-Sertant...	$0.5M	9	N/A	N/A	N/A

Add Company

Show More Biotech Companies

What Is Kaleido Biosciences?

Kaleido is a clinical-stage healthcare company leading the discovery and development of novel chemistries to drive functions of the microbiome organ to treat disease and improve human health. The company is advancing a robust pipeline of Microbiome Metabolic Therapies (MMTs) across a range of therapeutic areas, including rare genetic disorders. Kaleido's unique discovery and development model is redefining traditional R&D, enabling product candidates to advance rapidly into the clinic, dramatically reducing time and cost. Learn more at https://kaleido.com/.

keywords:N/A

$230.9M

Total Funding

Number of Employees

$855k

Revenue (est)

-6%

Employee Growth %

$94.1M

Valuation

N/A

Accelerator

Kaleido Biosciences News

2022-04-13 - Kaleido Biosciences is winding up operations as bluebird bio ...

Microbiome-focused company, Kaleido Biosciences, in a filing with the US Securities and Exchange Commission (SEC) on Friday, announced its...

2022-04-06 - Flagship's Kaleido Biosciences shuts down, as more biotechs ...

A few months after Flagship Pioneering spinout Kaleido Biosciences slashed 30 percent of its workforce, the company said it is shutting down...

2022-04-06 - Microbiome biotech Kaleido Biosciences shutters amid cash ...

Kaleido was formed in 2015 by Flagship Pioneering, a venture capital firm whose other microbiome portfolio companies include Seres Therapeutics...

2021-08-09 - Kaleido Biosciences : Announces New Chairperson Appointment to its Board of Directors

LEXINGTON, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced the appointment of current Boa ...

2021-04-21 - KALEIDO BIOSCIENCES, INC. Kaleido Biosciences : Announces Collaboration with Robert Jenq, M.D., to Explore Potential of its Microbiome Metabolic Therapies (MMT) in Preventing Febrile Neutropenia

LEXINGTON, Mass. - Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a small molecule driven approach to targeting the microbiome to treat disease and improve human health, today announced a research collaboration with researcher Robert Jenq, M.D. Professor of ...